Article Text

PDF
FRI0358 Short Term Prognosis of A Prospectively Followed Cohort of Unselected Adult IGA Vasculitis Cases – A Single Rheumatology Centre Experience
  1. J. Ostrovršnik,
  2. A. Hočevar,
  3. Ž. Rotar,
  4. M. Tomšič
  1. Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia

Abstract

Background The acute phase of adult IgA vasculitis (IgAV) is well characterized. Data of even short-term prognosis of adult IgAV is scarce, mostly retrospective and usually limited to patients with significant renal disease.

Objectives Our aim was to examine the short-term prognosis in a cohort of unselected adult IgAV cases.

Methods We analysed medical records of newly diagnosed, histologically proven cases of IgAV at our department of rheumatology between 1 January 2010 and 30 June 2015, that were followed until 31 December 2015.

Results We identified 139 IgAV cases during the observation period. The clinical characteristics at presentation and the initial treatment are shown in Table 1. During the acute phase of the disease 3/139 patients died (2 due to active vasculitis, 1 due to generalized CMV infection and heart failure). Twenty patients were lost to follow-up. The clinical characteristics of the remaining 116 patients who were followed for a median 8.9 (IQR 5.5 – 22.7) months at follow-up are shown in Table 2. During the follow-up new malignancy was diagnosed in 6/116 (5.2%) patients and 8/116 (6.9%) patients died. All deaths were due to causes unrelated to IgAV.

Table 1.

Clinical characteristics at presentation and initial treatment of IgAV

Table 2.

Clinical characteristics at last follow-up visit

Conclusions Contrary to the experience in children, IgAV in adults does not seem to be a benign disease even in the short-term. Admittedly, it is impossible to conclude whether this is due to the nature of the adult IgAV or because adults have more comorbidities than children.

Disclosure of Interest None declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.